AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s valuation.

According to A.I. Stock Analysis, Roku has earned an overall score of 75 out of 100. The stock’s score and upgraded rating are supported by an upbeat earnings call sentiment and favorable technical ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over 375 clinical trials. See why ABBV stock is a Buy.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

This does not mean that the stock is going to rise in the near-term but ... or by doing your own similarity analysis. According to Benzinga Pro, AbbVie's peer group average for short interest as a ...

AbbVie (ABBV) has recently been on Zacks.com's list of the ... present value of its future stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how ...